Two Drugs Are Better Than One. A Short History of Combined Therapy of Ovarian Cancer

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2016 Jan 22

PMID 26793017

Citations 13

Authors

Barbara Bukowska

Arkadiusz Gajek

Agnieszka Marczak

Affiliations

Soon will be listed here.

Abstract

Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin. The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.

Citing Articles

A Multi-Faceted Analysis Showing Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis.

Balcerak A, Szafron L, Rubel T, Swiderska B, Bonna A, Konarzewska M Int J Mol Sci. 2024; 25(8).

PMID: 38673965 PMC: 11050281. DOI: 10.3390/ijms25084381.

A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases.

Shen F, Huang J, Yang K, Sun C Onco Targets Ther. 2023; 16:485-495.

PMID: 37408994 PMC: 10318107. DOI: 10.2147/OTT.S415399.

A technical note on emerging combination approach involved in the onconanotherapeutics.

Iqubal M, Kaur H, Md S, Alhakamy N, Iqubal A, Ali J Drug Deliv. 2022; 29(1):3197-3212.

PMID: 36226570 PMC: 9578464. DOI: 10.1080/10717544.2022.2132018.

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma.

Nunes M, Duarte D, Vale N, Ricardo S Cancers (Basel). 2022; 14(18).

PMID: 36139522 PMC: 9496819. DOI: 10.3390/cancers14184357.

Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.

Kamal M, Mandour Y, Abd El-Aziz M, Stein U, El Tayebi H Molecules. 2022; 27(17).

PMID: 36080304 PMC: 9457820. DOI: 10.3390/molecules27175537.

References

Lee F, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson R . Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2008; 63(2):201-12. DOI: 10.1007/s00280-008-0727-5. View

McGuire 3rd W . Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol. 2003; 21(10 Suppl):133s-135s. DOI: 10.1200/JCO.2003.01.066. View

Chaires J, Leng F, Przewloka T, Fokt I, Ling Y, Perez-Soler R . Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem. 1997; 40(3):261-6. DOI: 10.1021/jm9607414. View

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

Brooks T, OLoughlin K, Minderman H, Bundy B, Ford L, Vredenburg M . The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs. 2006; 25(2):115-22. DOI: 10.1007/s10637-006-9018-3. View

Rogalska A, Marczak A, Gajek A, Szwed M, Sliwinska A, Drzewoski J . Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro. 2012; 27(1):239-49. DOI: 10.1016/j.tiv.2012.09.006. View

Haj H, Salerno M, Priebe W, Kozlowski H, Garnier-Suillerot A . New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem Biol Interact. 2003; 145(3):349-58. DOI: 10.1016/s0009-2797(03)00061-9. View

Villamarin S, Ferrer-Miralles N, Mansilla S, Priebe W, Portugal J . Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem Pharmacol. 2002; 63(7):1251-8. DOI: 10.1016/s0006-2952(02)00865-1. View

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

10.

Tallarida R . Interactions between drugs and occupied receptors. Pharmacol Ther. 2006; 113(1):197-209. PMC: 2045509. DOI: 10.1016/j.pharmthera.2006.08.002. View

11.

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P . Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28(20):3323-9. DOI: 10.1200/JCO.2009.25.7519. View

12.

Matei D, Emerson R, Schilder J, Menning N, Baldridge L, Johnson C . Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. 2008; 113(4):723-32. DOI: 10.1002/cncr.23605. View

13.

Gessner P . Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995; 105(2-3):161-79. DOI: 10.1016/0300-483x(95)03210-7. View

14.

Mundhenke C, Weigel M, Sturner K, Roesel F, Meinhold-Heerlein I, Bauerschlag D . Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol. 2008; 134(12):1397-405. DOI: 10.1007/s00432-008-0408-0. View

15.

Dragojew S, Marczak A, Maszewski J, Ilnicki K, Jozwiak Z . The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2007; 13(2):182-94. PMC: 6275653. DOI: 10.2478/s11658-007-0045-7. View

16.

Rogalska A, Gajek A, Szwed M, Jozwiak Z, Marczak A . The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol In Vitro. 2011; 25(8):1712-20. DOI: 10.1016/j.tiv.2011.08.009. View

17.

McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334(1):1-6. DOI: 10.1056/NEJM199601043340101. View

18.

Patankar N, Pritchard J, van Grinsven M, Osooly M, Bally M . Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clin Cancer Res. 2013; 19(4):865-77. DOI: 10.1158/1078-0432.CCR-12-2459. View

19.

Karbownik A, Szalek E, Urjasz H, Gleboka A, Mierzwa E, Grzeskowiak E . The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemp Oncol (Pozn). 2013; 16(5):435-9. PMC: 3687456. DOI: 10.5114/wo.2012.31775. View

20.

OMalley D, Richardson D, Rheaume P, Salani R, Eisenhauer E, McCann G . Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011; 121(2):269-72. DOI: 10.1016/j.ygyno.2011.01.009. View